Nurix Therapeutics NRIX Stock
Nurix Therapeutics Price Chart
Nurix Therapeutics NRIX Financial and Trading Overview
| Nurix Therapeutics stock price | 16.74 USD |
| Previous Close | 10.97 USD |
| Open | 10.92 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 1100 |
| Day's Range | 10.7 - 11.22 USD |
| 52 Week Range | 8.34 - 19.91 USD |
| Volume | 275.39K USD |
| Avg. Volume | 346.63K USD |
| Market Cap | 527.12M USD |
| Beta (5Y Monthly) | 1.688292 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.66 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.27 USD |
NRIX Valuation Measures
| Enterprise Value | 253.99M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.2772858 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 12.643457 |
| Price/Book (mrq) | 1.9234763 |
| Enterprise Value/Revenue | 6.092 |
| Enterprise Value/EBITDA | -1.418 |
Trading Information
Nurix Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.688292 |
| 52-Week Change | -0.089% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 19.91 USD |
| 52 Week Low | 8.34 USD |
| 50-Day Moving Average | 10.27 USD |
| 200-Day Moving Average | 11.38 USD |
NRIX Share Statistics
| Avg. Volume (3 month) | 346.63K USD |
| Avg. Daily Volume (10-Days) | 265.17K USD |
| Shares Outstanding | 47.45M |
| Float | 36.28M |
| Short Ratio | 20.88 |
| % Held by Insiders | 3.48% |
| % Held by Institutions | 95.94% |
| Shares Short | 5.2M |
| Short % of Float | 11.21% |
| Short % of Shares Outstanding | 10.96% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | November 30, 2022 |
| Most Recent Quarter (mrq) | February 28, 2023 |
| Next Fiscal Year End | November 30, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -441.52% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -28.48% |
| Return on Equity (ttm) | -61.57% |
Income Statement
| Revenue (ttm) | 41.69M USD |
| Revenue Per Share (ttm) | 0.82 USD |
| Quarterly Revenue Growth (yoy) | 31.80% |
| Gross Profit (ttm) | -145870000 USD |
| EBITDA | -179164992 USD |
| Net Income Avi to Common (ttm) | -178560000 USD |
| Diluted EPS (ttm) | -3.58 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 277.15M USD |
| Total Cash Per Share (mrq) | 5.84 USD |
| Total Debt (mrq) | 10.66M USD |
| Total Debt/Equity (mrq) | 3.89 USD |
| Current Ratio (mrq) | 4.444 |
| Book Value Per Share (mrq) | 5.776 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -165628992 USD |
| Levered Free Cash Flow (ttm) | -77723872 USD |
Profile of Nurix Therapeutics
| Country | United States |
| State | CA |
| City | San Francisco |
| Address | 1700 Owens Street |
| ZIP | 94158 |
| Phone | 415 660 5320 |
| Website | https://www.nurixtx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 297 |
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing DeTIL-0255, a drug-enhanced investigational cell therapy product that uses NX-0255 ex vivo to enhance tumor infiltrating lymphocytes propagation and phenotypic characteristics. The company has a strategic collaboration agreement with Gilead Sciences, Inc. to discover, develop, and commercialize a pipeline of protein degradation drugs for patients with cancer and other challenging diseases; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
Q&A For Nurix Therapeutics Stock
What is a current NRIX stock price?
Nurix Therapeutics NRIX stock price today per share is 16.74 USD.
How to purchase Nurix Therapeutics stock?
You can buy NRIX shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Nurix Therapeutics?
The stock symbol or ticker of Nurix Therapeutics is NRIX.
Which industry does the Nurix Therapeutics company belong to?
The Nurix Therapeutics industry is Biotechnology.
How many shares does Nurix Therapeutics have in circulation?
The max supply of Nurix Therapeutics shares is 49.15M.
What is Nurix Therapeutics Price to Earnings Ratio (PE Ratio)?
Nurix Therapeutics PE Ratio is now.
What was Nurix Therapeutics earnings per share over the trailing 12 months (TTM)?
Nurix Therapeutics EPS is -2.66 USD over the trailing 12 months.
Which sector does the Nurix Therapeutics company belong to?
The Nurix Therapeutics sector is Healthcare.
Nurix Therapeutics NRIX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}